Issues
-
Cover Image
Cover Image
Cancer mortality rates are usually reported as composite age-adjusted rates. These rates have been declining modestly since the 1990s. However, these statistics (which represent a weighted average of all age groups) heavily emphasize the experience of the oldest Americans, for whom mortality rates are the highest. As a result, trends emerging in younger Americans can be concealed. As an alternative to age adjustment, the authors examined cancer mortality rates stratified by age and birth cohort. This analysis revealed that every cohort of Americans born since the 1920s has experienced a progressive decline in cancer mortality rates at every age for which data is available. These results suggest that the efforts of researchers and practitioners to more effectively prevent, detect, and treat cancer have had a significant impact on our population's cancer mortality risk over the past half century. For details, see the article by Kort and colleagues on page 6500 of this issue. - PDF Icon PDF LinkTable of Contents
Cancer Research
Table of Contents
Reviews
Meeting Report
Perspectives in Cancer Research
Priority Report
Cell, Tumor, and Stem Cell Biology
Down-regulation of CXCR4 and CD62L in Chronic Lymphocytic Leukemia Cells Is Triggered by B-Cell Receptor Ligation and Associated with Progressive Disease
Clinical Research
Endocrinology
Epidemiology
Atopic Disease and Risk of Non–Hodgkin Lymphoma: An InterLymph Pooled Analysis
Premenopausal Mammographic Density in Relation to Cyclic Variations in Endogenous Sex Hormone Levels, Prolactin, and Insulin-like Growth Factors
Experimental Therapeutics, Molecular Targets, and Chemical Biology
Discovery of BMS-641988, a Novel and Potent Inhibitor of Androgen Receptor Signaling for the Treatment of Prostate Cancer
A Nanoparticle System Specifically Designed to Deliver Short Interfering RNA Inhibits Tumor Growth In vivo
Proteasome Inhibition Causes Regression of Leukemia and Abrogates BCR-ABL–Induced Evasion of Apoptosis in Part through Regulation of Forkhead Tumor Suppressors
Small-Molecule Multidrug Resistance–Associated Protein 1 Inhibitor Reversan Increases the Therapeutic Index of Chemotherapy in Mouse Models of Neuroblastoma
Immunology
The Dendritic Cell–like Functions of IFN-Producing Killer Dendritic Cells Reside in the CD11b+ Subset and Are Licensed by Tumor Cells
Molecular Biology, Pathobiology, and Genetics
Identification of Nectin-4 Oncoprotein as a Diagnostic and Therapeutic Target for Lung Cancer
Prevention
Systems Biology and Emerging Technologies
Tumor Microenvironment
Letters to the Editor
Corrections
Journal Archive
Cancer Research
(1941-Present; volumes 1-current)Published twice monthly since 1987. From 1941-1986, published monthly.
(ISSN 0008-5472)
The American Journal of Cancer
(1931-1940; volumes 15-40)Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.
(ISSN 0099-7374)
The Journal of Cancer Research
(1916-1930); volumes 1-14)Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.
(ISSN 0099-7013)
Advertisement
NOTICE: This notice serves to inform the reader that, in 2023, AACR received a donation by Pfizer of the rights to royalties from the sale—within the United States—of Bavencio® (avelumab), a pharmaceutical owned by Merck. None of these funds are being, or will be, used to directly support any specific publication or author. If an individual article is published that deals with this particular drug, such article will include standard financial disclosures per AACR journal policy. For more detail regarding AACR’s established policies for authors, please go to https://aacrjournals.org/pages/editorial-policies#coi.